Flaherty Financial News Newsletter Publications
Flaherty Financial News Inc.
Brian Flaherty is a LinkedIn member. For two people to connect, one must invite the other and then the other must accept the Invitation. If the person being invited to connect is not already on LinkedIn, they'll need to join in order to accept the Invitation.
Join Our Newsletter Mailing List: CLICK HERE
If you would like to submit some ideas for future sponsored newsletter subject matter, we are always looking for undervalued companies that feel they need exposure to increase their stock price! Contact:
Robert J. Flaherty
We continue to spotlight overlooked bargains and unknown quality efforts with the help of our friends in the financial community.
John & Bob Loved To Exchange Ideas.
Sir John's wisdom lives on: Our spiritual and financial pathfinder Sir John Templeton ( left ) exchanging ideas with editor Bob Flaherty has "gone home" as Sir John called dying. His wisdom lives on.
Look globally in every country for bargains. Seek the least popular and best buys as measured by comparative price- earnings ratios and other value screens. Be contrarian. When nearly everyone thinks and acts quarterly, have the discipline to look out at least three years and buy what will become popular again. Take profits and invest some of your gains in new bargains. Be humble! When you make a mistake admit it as quickly as possible. Diversify by industry, investment style and especially geographic region. In this unpredictable world, no more than 25% of your equity holdings should be invested in the stocks of any one country, especially your own. Don't sit on too much cash. Remember you will never live to see a year when a U.S. dollar will buy in December as much as it did in January! Above all, be optimistic for the long run. Don't waste time worrying. In the short run try to turn every negative into a positive. Stress positive thinking! Have purpose. Everyday focus on what is positive and productive. See opportunities you would of missed. Happiness can not be found by seeking it directly. It is a by product of living a life of serving others.
Our Treasure Chest of Ideas
Our annual “Favorites of the Famous” recommendations, started when Bob was a senior editor at Forbes Magazine, continued when he was editor of Equities Magazine and still comes out today in an annual issue of Flaherty Financial News Newsletter.The combined portfolios of our panels of wise men and women have beaten the S&P 500 18 out of 26 efforts, including a streak of 13 consecutive times. This is one of the best long-term track records of an annual favorite stock feature anywhere on the planet. We still get HIGH with the help of our friends.
Digital Copyright © 2017 Flaherty Financial News Inc. All Rights Reserved
International investors flew from Medellin over 500 miles deeper toward the Columbian border with Ecuador before transferring to military helicopters which landed guided by brush fires lit by heavily armed soldiers. Everyone exiting, including South American Gold President Ray De Motte (left) and Editor Bob Flaherty (right) , was ordered to keep moving quickly because FARC guerillas were rumored to be in the area. Next came a bumpy winding ride up around a mountain to South American Gold's (SAGD.OB) initial Santacruz Gold Project in the least explored most dangerous and therefore least picked over part of Columbia. Alas SAGD terminated the venture but the ride was fun.
We experiment to get spectacular response.
We featured enhanced CEO conference presentations to very small
groups in highly readable old Forbes
short story style snapshots.
At 83 Bob still feels a thrill hitting one more pitch out of the ballpark! Please consider making your company or fund one of our CEO Presentation Profiles or a BUY report in an upcoming issue.
March 20, 2017
Flaherty Financial News Newsletter #57
At last we have progress. After meeting with the FDA, CEL-SCI (NYSE:CVM) has come up with a plan to address the FDA's partial hold issues on CEL-SCI's unique pivotal global Phase 3 head and neck cancer study with its drug treatment Multikine. Pursuant to the partial hold, patients currently receiving study treatments can continue to receive treatment at the discretion of their physicians and with their consent. Patients already enrolled will continue to be followed. Globally 928 patients are enrolled in the study.
The news is after meeting with the FDA CEL-SCI believes the plan could lead to a favorable decision by the FDA to lift the FDA partial hold. Naturally, the future is unknowable and the FDA upon review of CEL-SCI's submission may or may not lift the partial hold. For more detailed information please visit http:www.cel-sci.com/
Meanwhile, the seemingly endless current hearing on CEL-SCI's $150 million arbitration suit against its original dismissed clinical research organization now rolled up into a giant continues. Again the future is unknowable and CEL-SCI could lose. But if CEL-SCI settles for a sizable sum or wins its case CEL-SCI's stock value should soar with its expanded ability to execute its immunotherapy dreams.
We'd stick with CEL-SCI stock until these key question marks on the FDA partial hold and the outcome of the $150 million arbitration suit become clarified. CEL-SCI's revolutionary unique pivotal treatment of cancer patients before their immune systems have been devastated by today's standard of deadly chemo and brutal radiation is too important to give up on while there is still hope.
Also in this issue: Ideas from NYC's Bio CEO & Investor conference plus now fired crusading U.S. attorney Preet Bharara announces the Invisible Man Jason Galanis is sentenced to over 11 years in prison.
Click Here Direct Link To Report
December 9, 2016
CEL-SCI announced pricing of a new public offering at $0.125. While highly dilutive , the offering is needed to provide liquidity to survive as the $150 million arbitration hearing suit is settled or decided. Offering proceeds will continue development of CEL-SCI's lead Phase III global study drug Multikine, its potential vaccine for the treatment of rheumatoid arthritis L.E.A.P.S. and general uses.
October 27, 2016
THE FDA LETTER ARRIVES!
On Oct. 21st CEL-SCI received its expected Partial Clinical Hold Letter and has started working on a response to the FDA. Management plans to work diligently with the FDA with the goal of having the partial clinical hold lifted. Also CEL-SCI continues fighting to win its $50 arbitration suit hearing with an extra possible $100 million in consequential damages against its dismissed initial Clinical Research Organization. Flaherty Financial News believes that staying the course is the wisest move for readers. -RJF
April 6, 2016
Flaherty Financial News Newsletter #56
35th Flaherty's Favorites of the Famous: Ten Stocks for Tomorrow!
February 1, 2016
November 20, 2014
July 23, 2013
September 11, 2011
February 2, 2011
January, February and March: CEL-SCI Corporation (NYSE:CVM), Digital Switch Corp. , Ergomed plc (AIM:ERGO) , Keating Wealth Management, Sir John Templeton's stock advice in falling markets. Wow! Dow 89,000! Sir John's forgotten forecast. April: Flaherty's 35th Annual FAVORITES OF THE FAMOUS: Ten Stocks for tomorrow: AK Transneft, Bovie Medical, CEL-SCI, Fairfax Financial, Hertz Global Holdings, Myers Industries, National Commerce Corp., Sintex Technologies, Total S.A., Zebra Technologies Corp.
Golden Oldies: July 13, 2007
- our very first issue of Flaherty
Financial News issue: Pre-Paid
Legal Services Inc. is a
classic case history on how to defeat abusive short sellers.
Bob Flaherty notes that there is nothing wrong with legitimate short
selling. However, abusive short selling where proper share borrowing
is not followed or manipulative untrue rumors are spread can lead to the
destruction or stunting the growth of many promising ventures. Besides testifying before Congress on the subject, Flaherty
has written or edited over 100 articles on abusive short sellling and been
labeled "a crusader" who has been responsible for many reforms. The ShortBuster Day his old friend
gadfly Ray Dirks and Bob ran spotlighted good things about 30
companies that the main stream press which was close to many abusive
shorts neglected to include. Under unfair attack by
secret naked short sellers, Pre-Paid Legal Services, SafeCard
Services (which had been attacked over 30 consecutive times by Barron's)
and totally ignored
Cheyenne Software saw their shares zoom. All hell broke loose when Wholesome & Hearty's
idealistic founder finally got to tell his side. A sickly youth, he dedicated himself to
helping people eat better so they would live longer. The instant his dream
went public he was branded a bad guy! There was an avalanche of naked short
selling and smears. However his IPO had not yet deposited
shares to borrow. That ment the huge short position was mostly naked because there were no shares to legally borrow.
Overnight the short position disappeared. That stock rose 540%- more
than any other stock on
NASDAQ that year. Earlier with Cameron Associates IR founder
Rod O'Connor, Bob ran The Short Symposium which led to important reforms. Alas recently new abusive shorts, some secret, have arisen to plague job
creating CEOs. We hope regulators will get after the abusers before 1,000
companies are killed! That is how many companies went under the last time
sleepy regulators didn't do their jobs and act promptly until Congress called them on the
Nov. 29, 2014: Remembering the fairy tale life of one of America's first female financial writers courageous Clare Reckert. The New York Times' first female financial writer and it's first to get a Times' byline, Clare had to misspell her first name Claire without an (i). A male boss wanted readers to think she was a man. Her efforts for gender parity at The New York Times infuriated the males so much her passing at age 100 didn't receive even a single line of obit in the print edition of the paper. Way to go guys!
Disclaimer- Flaherty Financial News Inc. Charges for some of our services such as advertising, audience distribution, conference presentations, sponsored profiles, sponsored special situation buy reports and PDF reprints. Where we have conflicts we will disclose our receipts of cash or stock in the relevant newsletter and update any additional payments decided upon afterwards as they occur in subsequent issues. This is a hybrid journalistic effort where some copy is sponsored and some is not.
This website and our archived newsletters contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. We caution readers not to place undue reliance on any forward-looking statements and to supplement our information with specific company SEC filings and their own research. Please be aware that there is risk in every company you buy and the smaller the company, usually the greater the risk. Coverage or other mention of a stock on this website or in a newsletter is neither an offer nor solicitation to buy or sell any securities mentioned. We are not investment dealers or investor advisers registered with the SEC or State Security Authorities. We do not guarantee all the information on this website or in any FFN newsletter is correct, timely or will be updated. Remember some errors are inevitable. Reproduction without written permission from FFN is forbidden. From time to time our staff or Flaherty Financial News Inc. may be a shareholder of any individual company profiled in our newsletters or named on our website. Our editorial policy forbids editorial from buying or selling any stock mentioned in a particular issue until this particular issue is out at least ten business days. In cases where FFN receives compensation for writing a profile or report or for extra distribution we warn that such sponsored coverage becomes similar to an advertorial and does not have the same degree of independence as unpaid unsponsored coverage. As FFN editor I always reserve “Final Copy Responsibility” on what to include and what to leave out of every article and report. We try to be objective, but may fail. We are not security analysts or stockbrokers but financial journalists with all the failings of that profession. You readers must decide the merits of each company yourselves and whether it is suitable for you as an investment. Bob Flaherty, Editor.
Flaherty Financial News Inc. (FFN) and its newsletters Flaherty Financial News and Flaherty Special Situations are not registered as broker dealers or investment advisers with the U.S. Securities and Exchange Commission or any state securities authority. Our newsletters and their information and content providers make no representations or warranties of any kind in connection with the subject matter, performance or suitability of the information contained in the publications for any purpose and are not liable for the timeliness, accuracy or completeness of the information. The information is provided for general information purposes and is not a substitute for obtaining professional advice from a qualified person or entity familiar with your personal circumstances. Please seek the help and advice of professionals as appropriate regarding the evaluations of any specific security, report, opinion, advice or other content. FFN is not responsible for trades placed by recipients. All opinions expressed, information and date provided are subject to change without notice. FFN, its officers and its employees may have positions in and may from time to time make purchases or sales of the securities discussed or mentioned by FFN. (However, we will avoid front running and the buying or selling of any security about to be discussed until ten business days after our particular report is released to the public.) FFN shall have no liability for any newsletter that is lost, intercepted or not received in a timely manner, or not received at all, for any reason.
Digital Copyright © 2017 Flaherty Financial News Inc. All Rights Reserved